Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men
- PMID: 20059581
- DOI: 10.1111/j.1365-2605.2009.01029.x
Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men
Abstract
Despite the burgeoning interest in the field of andrology, no studies have specifically addressed the impact of serum testosterone levels on healthcare utilization and costs. We analysed data from the population-based cohort Study of Health in Pomerania (SHIP), Germany, to assess the association of serum testosterone levels with self-reported health care utilization and costs at baseline and at 5 years follow up. Study sample comprised 2023 men at baseline, of whom 1530 men were repeatedly examined. Low and high serum testosterone levels, defined according to the age-specific 10th and 90th percentile, were compared with reference subjects with serum testosterone levels ≥10th -≤90th percentile. Two-part econometric models were applied adjusting for socio-economic and medical confounders. Cross-sectional models revealed higher numbers of outpatient visits and higher costs for both, men with low (+19.1 and +19.9%, respectively) and high serum testosterone levels (+25.3 and +30.2%, respectively), whereas number of inpatient days and costs were not associated with serum testosterone levels. Adjustment for age, educational level, income, waist circumference, smoking status, physical activity and alcohol consumption did not considerably alter the results. Longitudinal models revealed a significant association of low serum testosterone levels with increased number of follow-up outpatient visits (age-adjusted: +28.6%) and costs (+38.0%) only. Low and high serum testosterone levels were associated with increased short-term outpatient health care costs, whereas low serum testosterone levels appear to be predictive of long-term outpatient health care costs. Cost-effectiveness studies of available treatments are necessary to identify benefits for physicians, patients and health care system as a whole.
© 2010 The Authors. International Journal of Andrology © 2010 European Academy of Andrology.
Similar articles
-
Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.Gastroenterology. 2008 Jan;134(1):85-94. doi: 10.1053/j.gastro.2007.10.024. Epub 2007 Oct 18. Gastroenterology. 2008. PMID: 18005961
-
Direct medical costs of COPD--an excess cost approach based on two population-based studies.Respir Med. 2012 Apr;106(4):540-8. doi: 10.1016/j.rmed.2011.10.013. Epub 2011 Nov 18. Respir Med. 2012. PMID: 22100535
-
Healthcare utilization and costs of patients with rosacea in an insured population.J Drugs Dermatol. 2008 Jan;7(1):41-9. J Drugs Dermatol. 2008. PMID: 18246697
-
Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006.Spine (Phila Pa 1976). 2009 Sep 1;34(19):2077-84. doi: 10.1097/BRS.0b013e3181b1fad1. Spine (Phila Pa 1976). 2009. PMID: 19675510
-
[Bridging sectoral barriers with integrative care].Internist (Berl). 2020 Sep;61(9):903-911. doi: 10.1007/s00108-020-00843-8. Internist (Berl). 2020. PMID: 32734335 Review. German.
Cited by
-
Cohort profile: Greifswald approach to individualized medicine (GANI_MED).J Transl Med. 2014 May 23;12:144. doi: 10.1186/1479-5876-12-144. J Transl Med. 2014. PMID: 24886498 Free PMC article.
-
Hypogonadism and its associated factors among adult male type 2 diabetes mellitus patients at the university of gondar comprehensive specialized hospital, Northwest Ethiopia 2024: A comparative cross-sectional study.PLoS One. 2025 Aug 14;20(8):e0329784. doi: 10.1371/journal.pone.0329784. eCollection 2025. PLoS One. 2025. PMID: 40811476 Free PMC article.
-
Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review.Clinicoecon Outcomes Res. 2021 Jan 12;13:31-38. doi: 10.2147/CEOR.S285434. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 33488103 Free PMC article. Review.
-
Improving the annual monitoring rates of testosterone replacement therapy patients in primary care.BMJ Open Qual. 2022 Aug;11(3):e001784. doi: 10.1136/bmjoq-2021-001784. BMJ Open Qual. 2022. PMID: 35914817 Free PMC article.
-
Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.Urol Oncol. 2016 Dec;34(12):530.e9-530.e14. doi: 10.1016/j.urolonc.2016.07.004. Epub 2016 Sep 22. Urol Oncol. 2016. PMID: 27665357 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical